Target Validation

All of our target protein candidates are first-in-class entities discovered via our proprietary predictive discovery platforms. Therefore, following the in silico discovery process, our novel targets are relayed to a therapeutically focused validation process, which is performed in-house as well as via scientific collaborations with top academic laboratories. Promising validated targets are then advanced in our mAb therapeutics pipeline.